Korean Dong-A In Talks With Warner Chilcott For Additional Indications For ED Drug Zydena
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Dong-A Pharmaceutical says its U.S. partner Warner Chilcott is seeking an expanded indication of lower urinary track symptoms for its erectile dysfunction drug Zydena (udenafil)